Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. - Wikidata - wikimedia - TriplyDB

Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer.

Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer.

http://www.wikidata.org/entity/Q34321215

about

Genome-wide analysis of microRNA and mRNA expression signatures in cancer Open tubular lab-on-column/mass spectrometry for targeted proteomics of nanogram sample amounts Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer Towards decision-making using individualized risk estimates for personalized medicine: A systematic review of genomic classifiers of solid tumors.Molecular staging of lymph node-negative colon carcinomas by one-step nucleic acid amplification (OSNA) results in upstaging of a quarter of patients in a prospective, European, multicentre study Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer Current status of gene expression profiling to assist decision making in stage II colon cancer Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?Liquid biopsy: monitoring cancer-genetics in the blood.Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors Daple is a novel non-receptor GEF required for trimeric G protein activation in Wnt signaling.IGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers Validation of a quantitative 12-multigene expression assay (Oncotype DX(®) Colon Cancer Assay) in Korean patients with stage II colon cancer: implication of ethnic differences contributing to differences in gene expression.A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency A new simple morphology-based risk score is prognostic in stage I/II colon cancers Practical guidance for implementing predictive biomarkers into early phase clinical studies.A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers Colorectal cancer biomarkers: to be or not to be? Cautionary tales from a road well travelled Biomarkers in precision therapy in colorectal cancer.Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer Use of a computerised decision aid (DA) to inform the decision process on adjuvant chemotherapy in patients with stage II colorectal cancer: development and preliminary evaluation.Biomarkers of colorectal cancer: recent advances and future challenges.Personalized treatment for patients with colorectal cancer: role of biomarkers.The preoperative platelet to lymphocyte ratio is a prognostic marker in patients with stage II colorectal cancer.Prognostic and Predictive Biomarkers in Colorectal Cancer: Implications for the Clinical Surgeon.Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria.Transcriptomics in cancer diagnostics: developments in technology, clinical research and commercialization.Mass spectrometry based translational proteomics for biomarker discovery and application in colorectal cancer.Impact of MLH1 expression on tumor evolution after curative surgical tumor resection in a murine orthotopic xenograft model for human MSI colon cancer.Translating colorectal cancer genetics into clinically useful biomarkers.From tumour heterogeneity to advances in precision treatment of colorectal cancer.Molecular Diagnostic Applications in Colorectal Cancer.Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence.Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective.Nomogram for predicting recurrence in stage II colorectal cancer.Identification of a multi-cancer gene expression biomarker for cancer clinical outcomes using a network-based algorithm.A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type Colon Cancer Reveals Intratumor Subtype Heterogeneity.In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer.Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I-II Colon Cancer.

P2860

Q26795603-23093DB7-3B5D-44C6-A65D-C7192AF65847 Q27312175-51C5B8D8-637C-4643-B786-A60EF03DDA46 Q30238915-51B14656-1DE9-48EA-85AF-AD1AF81B49BC Q30252422-7050FF1F-52E8-4197-A7F5-130163C1E6D8 Q33613616-FD674904-379F-4B18-94EE-0CC4D1DD0610 Q33750119-E21F1B01-5F73-49F6-8F43-BF0057648765 Q33829763-6C094244-9635-41B2-8AAB-E00100724DA0 Q34013786-955AF1B6-A796-474E-9414-A9F1E24CA10F Q34356149-2781704F-222F-4B30-8FC3-603F9D834900 Q34522228-C420D3FD-13DF-481F-808B-FF2A88CFF6D2 Q35057318-89F2DA13-9979-4127-A841-94437326CD04 Q35792269-2F75FFB6-8F43-4FE2-9927-3027C76C8141 Q36289304-B9A1A4DD-7FA0-4A4B-BC78-2E2F39E1EA09 Q36399053-4CA2637E-D9BD-456A-9A7F-B6BA2BD4EE43 Q36494964-151D6FD2-A08F-4788-AEFA-488F5D4A58F3 Q36902960-2243E22F-024D-4C76-BAEF-19213728ACE4 Q37286110-A4B0A220-2613-4DB3-B135-49B1F4301D6C Q37413869-A511E4DE-A2E1-4BA3-94A0-59AABBD63A01 Q37578725-769D7572-281D-4A9A-A05F-CC0868D597BB Q37609130-8F3B731E-60C4-421C-A57D-0A0C4C38B86C Q37711623-7971B821-FD9F-45A3-8FD3-85DEE5D5D5AD Q37728416-E6FF5A4D-9A78-4616-9D5D-A005B01C6A02 Q38259770-17741C54-D323-439B-93F7-FFB0F6A89BDD Q38390834-67E07D39-56C7-458C-8E58-F6B669E25BFC Q38518401-6A6BA508-6DE4-40D5-8E19-A3DECECB23A5 Q38555225-FA7F33C2-B69B-4169-A1AB-176A8E196134 Q38565991-6E52E020-A3EC-4888-B0F1-897EFDE0A91E Q38632574-D1AC5466-0632-417F-856D-339E2431398C Q38652227-D8661F08-A7D5-4345-958C-F289AD118415 Q38703244-73C479F0-1CC3-49F5-B8E4-2F6D8DB404D0 Q38779895-5783B2AB-CDFF-4618-BFA7-D622C45BD704 Q38786707-9D7160E4-28F7-4CFD-9D5E-B954AD408E9A Q38947671-3280E6CC-9D0E-4037-BD44-A0403781E620 Q39180723-ADEA26F0-05EE-4DAD-A5B3-79C7F6668AFE Q39381552-24C29F46-804F-40F6-8443-8632F0E3855A Q39434378-A07C2BE9-35EA-430C-9302-53D103DE940E Q41557019-97D4C0C8-32E1-49E5-A57F-A8B046EF357C Q51071981-5B4A392E-D625-47B1-ADBF-C53B3A8184A9 Q52989643-ABEBB036-D6BA-4395-99D7-982ED5FF2997 Q53028836-DB0C2062-60AC-43AB-BE7A-7A824C0A5BCD

P2860

Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer.

http://www.wikidata.org/entity/Q34321215

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Independent validation of a pr ...... ts with stage II colon cancer.

@ast

Independent validation of a pr ...... ts with stage II colon cancer.

@en

Independent validation of a prognostic genomic signature

@nl

type

label

Independent validation of a pr ...... ts with stage II colon cancer.

@ast

Independent validation of a pr ...... ts with stage II colon cancer.

@en

Independent validation of a prognostic genomic signature

@nl

prefLabel

Independent validation of a pr ...... ts with stage II colon cancer.

@ast

Independent validation of a pr ...... ts with stage II colon cancer.

@en

Independent validation of a prognostic genomic signature

@nl

P1433

Q34321215-CF157394-193B-4958-91D3-DE94CEF9774C

P1476

Q34321215-951BB49E-333F-494A-AA45-0A88CB33D436

P2093

Q34321215-3031A22D-C1A5-4C5C-96C6-F255EF5430D9

Q34321215-315BAE2E-25D0-47E9-85C7-C78E67A1FB27

Q34321215-488E5E38-4A85-4E14-BA31-2F122C29ACB5

Q34321215-4AB9D718-F444-4D3B-B5A8-712F3173E682

Q34321215-4FCFB242-57A8-45DA-B730-39C8073243EB

Q34321215-58B33CAD-573B-40B5-9707-D0815B784E30

Q34321215-91C47E44-45E8-4DBC-A256-615AA0AC6483

Q34321215-B80C0327-E6D3-473B-BF19-17E7462421BA

Q34321215-C04DD809-0075-482D-B008-609C650EEAEC

Q34321215-C3078446-FB2B-445E-A2CC-7D6712223549

P304

Q34321215-C0843F8B-4007-46EE-8579-C31820EB8F79

P31

Q34321215-A3D5A3F5-30A9-4025-8BC0-0618266CF738

P356

Q34321215-BEBDD86C-D66F-42C0-8ED9-D59ADC80A008

P407

Q34321215-B80ABB41-E001-4416-B2E3-0E48E3508575

P433

Q34321215-1DC43171-E8C7-4C9E-B437-6D3AB53D9A08

P478

Q34321215-6C229F08-C2B4-45EB-88E4-64FE1B0673D5

P50

Q34321215-DA668096-CEAA-443C-BD28-33DB75E23348

P577

Q34321215-954E7214-E27E-4B88-9FD6-D91760CEDBE8

P5875

Q34321215-F7C4BC31-C256-4F0F-96A2-8FEE68490525

P698

Q34321215-27F6C6C9-1439-4A34-9689-07F1E7D07E4D

P356

SLA.0B013E31827C1180

P1433

Annals of Surgery

P1476

Independent validation of a pr ...... ts with stage II colon cancer.

@en

P2093

Annuska M Glas

http://www.w3.org/2001/XMLSchema#string

Eliane Zeestraten

http://www.w3.org/2001/XMLSchema#string

Gisela Keller

http://www.w3.org/2001/XMLSchema#string

Inès Goossens

http://www.w3.org/2001/XMLSchema#string

Iris Simon

http://www.w3.org/2001/XMLSchema#string

Klaus-Peter Janssen

http://www.w3.org/2001/XMLSchema#string

Matthias Maak

http://www.w3.org/2001/XMLSchema#string

Mireille Snel

http://www.w3.org/2001/XMLSchema#string

Paul Roepman

http://www.w3.org/2001/XMLSchema#string

Robert Rosenberg

http://www.w3.org/2001/XMLSchema#string

P304

1053-1058

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/SLA.0B013E31827C1180

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

257

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234086139

http://www.w3.org/2001/XMLSchema#string

P698

23295318

http://www.w3.org/2001/XMLSchema#string